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ABSTRACT
Background. Major oncologic surgery is associated with a
high incidence of thromboembolic events (TEE). Addition
of perioperative chemotherapy in esophageal cancer sur-
gery may increase the risk of TEE.
Methods. The thromboembolic toxicity proﬁle was ana-
lyzed in patients with esophageal adenocarcinoma (EAC).
Two groups were identiﬁed: patients who underwent
esophagectomy and received perioperative chemotherapy
with epirubicin, cisplatin, and capecitabine (ECC; n = 52),
and patients who were treated with surgery alone (n = 35).
Results. A total of 22 TEEs was observed in 17 patients
(32.7%) in the chemotherapy group and 3 patients (7.5%)
in the surgery-alone group (P\.01). The relative risk of
developing a TEE for patients receiving perioperative
chemotherapy during the whole treatment period was 3.8
(95% conﬁdence interval 1.2–12.0). A preoperatively
occurring TEE did not increase the risk of postoperative
TEE, nor did it increase postoperative hospital stay
(P = .325). Median postoperative hospital stay was
23 days (range 14–78) for patients with a postoperative
TEE and 15 days (range 10–105) for patients without TEE
(P = .126). Perioperative chemotherapy with the epirubi-
cin, cisplatin, and capecitabine regimen was independently
associated with the development of TEE in the combined
preoperative and postoperative period (P = .034).
Conclusions. Perioperative chemotherapy improves sur-
vival for operable esophageal cancer but comes at the price
of toxicity. Perioperative chemotherapy for EAC increases
the risk of TEE. However, chemotherapy-related preoper-
ative TEE did not increase the risk of postoperative TEE,
nor did it increase postoperative hospital stay, justifying its
use in clinical practice.
In the Western world, esophageal adenocarcinoma
(EAC) has become the most prevalent type of cancer in
the esophagus, overtaking squamous cell carcinoma.
1–3
Perioperative treatment of patients with operable adeno-
carcinoma of the distal esophagus, gastroesophageal
junction, and stomach with chemotherapy consisting of
epirubicin, cisplatin, and 5-ﬂuorouracil improves overall
survival in patients when compared to surgery alone.
4 The
regimen consists of three preoperative treatment cycles
followed by surgery and three postoperative cycles. Oral
administration of capecitabine as an alternative for pro-
longed intravenous infusion of 5-ﬂuorouracil showed
equal efﬁcacy in patients with advanced or inoperable
esophagogastric cancer.
5 The epirubicin, cisplatin, and
capecitabine (ECC) regimen may be used as a substitute
for the epirubicin, cisplatin, and 5-ﬂuorouracil regimen.
6
Our current standard for patients with operable esopha-
geal and gastroesophageal junction adenocarcinoma is
perioperative chemotherapy with the ECC regimen com-
bined with radical esophagectomy and gastric conduit
reconstruction.
Gastroesophageal cancers are associated with the high-
est risk of venous thrombosis.
7 The reported incidence of
thromboembolic events (TEE) during chemotherapy for
advanced gastroesophageal cancer is approximately 12%
and even higher when patients are treated with cisplatin.
8
Another important risk factor for TEE is major (oncologic)
surgery.
9,10
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series of patients with advanced inoperable gastroesopha-
geal cancer. Little is known about the incidence and
consequences of TEE during perioperative chemotherapy
in patients with cancer of the upper gastrointestinal tract.
This study shows our experience of the past 4 years during
which the ECC protocol was applied in patients with EAC.
The thromboembolic toxicity proﬁle of patients receiving
perioperative ECC chemotherapy was analyzed and com-
pared with a group of patients from the same time period
who were treated with surgery alone.
METHODS
Data Collection
A prospective database of all esophageal resections in
our tertiary referral center (University Medical Center
Utrecht, Utrecht, the Netherlands) is collected continu-
ously. The research protocol was in accordance with the
guidelines of the medical ethics committee. Database
entries include standard patient characteristics, as well as
prospectively collected intra- and postoperative data. The
database enables entry of various complications, among
which deep venous thrombosis, pulmonary embolism, and
myocardial infarction form separate entries. Atrial ﬁbril-
lation was also documented in the database because this
condition is associated with both esophagectomy and an
increased risk of postoperative thromboembolic complica-
tions. Complications that occurred during preoperative
chemotherapy were retrieved from the patient records of
the medical oncology department.
Inclusion Criteria
The study population consisted of all consecutive
patients who underwent esophageal resection with gastric
conduit reconstruction for EAC complemented with peri-
operative ECC therapy (January 1, 2007, to February 1,
2011). To eliminate historical bias, the control group
comprised patients who underwent the same surgical
treatment without chemotherapy in that same time period
(surgery-alone group). Reasons for not commencing pre-
operative chemotherapy were T1 disease, weight loss
[10%, World Health Organization performance status[2,
and Groningen Frailty Index [3 (for patients above
70 years of age).
11,12
Chemotherapy
Patients eligible for perioperative ECC chemotherapy
received three preoperative treatment cycles and another
three postoperative treatment cycles. One chemotherapy
cycle consisted of intravenous administration of epirubi-
cin and cisplatin on day 1 (50 and 60 mg/m
2,
respectively), followed by 625 mg/m
2 of capecitabine
twice daily for 21 days. Adaptations to the regimen (i.e.,
dose reduction or change of regimen) were applied when
necessary on the basis of the occurrence of adverse events
during therapy as deﬁned by the Common Terminology
Criteria for Adverse Events (CTCAE) and the Common
Toxicity Criteria.
13
After completion of the second cycle, a computed
tomography (CT) scan was performed to evaluate response.
In case of tumor progression, a third cycle was not
administered, and surgery was rescheduled accordingly. In
case of a TEE during preoperative chemotherapy, antico-
agulative therapy was initiated with low-molecular-weight
heparin (Fragmin, Pﬁzer, New York, NY; daily; subcuta-
neous;\80 kg, 2500 IU;[80 kg, 5000 IU).
Surgical Therapy
Surgical therapy consisted of esophageal resection with
gastric conduit reconstruction through a transthoracic or
transhiatal approach performed by a single experienced
surgeon. Preferably, esophagectomy was performed with
the use of minimally invasive surgery. Transthoracic sur-
gery included two-ﬁeld lymphadenectomy. Abdominal
lymphadenectomy was similar for all patients (truncal and
perigastric). Operative approach was matched to patient
physiology and tumor characteristics. All esophagogastric
anastomoses were hand sewn and situated cervically on the
left side. Perioperatively, all patients received standard
thrombotic prophylaxis with low-molecular-weight heparin
(Fragmin, Pﬁzer; daily; subcutaneous; \80 kg, 2500 IU;
[80 kg, 5000 IU) and stockings.
Primary Outcome
The primary outcome was deﬁned as the occurrence of a
TEE during one of three distinct periods, as follows: (1) the
preoperative period, deﬁned as the day of diagnosis until
the day of surgery; (2) the postoperative period, deﬁned as
during the hospital stay or until the 30th day after surgery;
and (3) the postoperative chemotherapy period, from the
day on which postoperative chemotherapy was resumed
until 30 days after the last administration of chemotherapy.
The latter period was only applicable to those patients who
received postoperative chemotherapy. TEEs were deﬁned
and graded according to CTCAE version 4.03.
13 Only
events graded 2 or higher were included for analysis
(Table 1).
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Data were analyzed by SPSS statistical software, version
15.0 (SPSS, Chicago, IL). Cross-tabulation with chi-square
testing was used to identify differences between cohorts
regarding baseline characteristics and the occurrence of
TEE during separate and combined treatment periods.
Student’s t-test was used for continuous variables. Asso-
ciations between risk factors and TEE were analyzed with
univariate regression analysis. Multivariate logistic
regression was applied to correct for confounders. The
following risk factors and possible confounders with
respect to the development of TEE were identiﬁed before
analysis: age above 60 years, gender, body mass index
above 27, American Society of Anesthesiologists score,
chronic obstructive pulmonary disease (COPD), diabetes,
hypertension, previous TEE, history of smoking, length of
hospital stay, operative approach, operative time, presence
of tumor-positive lymph nodes, and tumor differentiation
grade. Anticoagulant use at the time of diagnosis was
included as a protective factor. A P-value of \.05 was
considered statistically signiﬁcant.
RESULTS
Between January1, 2007, andFebruary1,2011,atotal of
107 patients underwent esophagectomy with gastric conduit
reconstruction for EAC. After exclusion of patients who
receivedchemoradiotherapyorprimarychemotherapyother
than ECC, 87 patients remained. Mean age was 65 years,
and the ratio of men to women was approximately 4:1.
Cohorts and Baseline
Perioperative chemotherapy in the form of ECC was
administered to 52 patients. The remaining 35 patients did
not receive chemotherapy. Reasons for not giving chemo-
therapy are presented in Table 2.
Both age and gender were evenly distributed between
the surgery-alone group and the group receiving ECC. In
the surgery-alone group, more patients had a history of
COPD (28.6% vs. 11.5%, v
2 test P = .044). With regard to
other relevant medical history, no statistically signiﬁcant
differences were identiﬁed between the two groups
(Table 3).
Preoperative tumor staging with endoscopic ultrasound
(uT) showed more patients with early stage disease (uTis-1,
n = 11) in the surgery-alone group, as opposed to none in
the chemotherapy group. The number of patients with
advanced (uT3–4) disease was evenly dispersed over the
groups. Postoperative pathological tumor staging (pT)
showed no statistically signiﬁcant difference between the
two groups. An equal spread of differentiation grades was
observed. The number of patients with positive lymph
nodes at pathological examination was slightly higher in
the group that did not receive chemotherapy (65.7% vs.
46.2% in the chemotherapy group, v
2 test P = .073). The
majority of patients (73.1%) in the chemotherapy group
were operated on via a transthoracic approach, as opposed
to approximately half of the patients (51.4%) in the sur-
gery-alone group (v
2 test P = .039).
TABLE 1 TEE grades as deﬁned by the CTCAE
CTCAE
grade
Deﬁnition
1
a Venous thrombosis (e.g., superﬁcial thrombosis)
2 Venous thrombosis (e.g., uncomplicated deep vein thrombosis), medical intervention indicated
3 Thrombosis (e.g., uncomplicated pulmonary embolism [venous], nonembolic cardiac mural [arterial] thrombus), medical
intervention indicated
4 Life-threatening (e.g., pulmonary embolism, cerebrovascular event, arterial insufﬁciency), hemodynamic or neurologic instability,
urgent intervention indicated
5 Death
a Grade 1 not included for analysis
TABLE 2 Reasons for not receiving neoadjuvant chemotherapy in
35 of 87 patients
Characteristic n
Patient unﬁt for perioperative chemotherapy
a 17
Previous chemotherapy with serious toxicity 2
Weight loss[10% 2
Refused patient consent 2
Esophageal perforation requiring immediate intervention 1
Early-stage disease (uT B 1) 11
a Patients with a World Health Organization performance status of
[2 (corresponding to a Karnofsky score of \70) or a Groningen
Frailty Index[3 (for patients older than 70)
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surgery and perioperative chemotherapy according to the ECC regimen
Characteristic Surgery alone (n = 35) Surgery and ECC (n = 52) P
a
Pretreatment data
Gender .751
Male 28 (80.0%) 43 (82.7%)
Female 7 (20.0%) 9 (17.3%)
Age, years
Mean (SD) 66.9 (9.6) 64.4 (8.4) .198
b
[60 years 27 (77.1%) 35 (67.3%) .320
BMI[27 17 (48.6%) 26 (50.0%) .896
Medical history
DM 7 (20.0%) 7 (13.5%) .416
Hypertension 12 (34.3%) 22 (42.3%) .452
COPD 10 (28.6%) 6 (11.5%) .044
TEE 13 (37.1%) 12 (23.1%) .155
Anticoagulant therapy 3 (8.6%) 5 (9.6%) .869
Smoking 18 (51.4%) 29 (55.8%) .217
Ultrasound T stage .003
uTis 3 (8.6%) 0 (0.0%)
uT1 8 (22.9%) 0 (0.0%)
uT2 3 (8.6%) 12 (23.1%)
uT3 18 (51.4%) 36 (69.2%)
uT4 2 (5.7%) 2 (3.8%)
uTx 1 (2.9%) 2 (3.8%)
Surgical data
ASA score .116
1 8 (22.9%) 13 (25.0%)
2 17 (48.6%) 34 (65.4%)
3 9 (25.7%) 5 (9.6%)
4 1 (2.9%) 0 (0.0%)
Operative approach .039
Transhiatal 17 (48.6%) 14 (26.9%)
Transthoracic 18 (51.4%) 38 (73.1%)
Surgery type .850
Minimally invasive 27 (77.1%) 41 (78.8%)
Open 8 (22.9%) 11 (21.2%)
Tumor differentiation grade .807
Poor 14 (40.0%) 21 (40.4%)
Moderate 13 (37.1%) 17 (32.7%)
Well 1 (2.9%) 4 (7.7%)
Unknown 7 (20.0%) 10 (19.2%)
Pathologic tumor stage .079
pTis 1 (2.9%) 0 (0.0%)
pT0 0 (0.0%) 6 (6.5%)
pT1 11 (31.5%) 8 (15.4%)
pT2 2 (5.7%) 7 (13.5%)
pT3 19 (54.3%) 30 (57.7%)
pT4 2 (5.7%) 1 (1.9%)
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Overall, 20 patients experienced a total of 22 TEEs at
some stage during the three treatment periods (Table 4).
The observed TEEs included deep venous thrombosis
(n = 2), pulmonary embolism (n = 9), aorta thrombosis
(n = 2), portal vein thrombosis (n = 1), inferior caval vein
thrombosis (n = 1), myocardial infarction (MI; n = 2),
cardiac mural thrombosis (n = 1), and stroke (cardiovas-
cular accident; n = 4).
Within the group of patients receiving chemotherapy, 17
patients (32.7%) experienced a TEE. Three patients (7.5%)
were diagnosed with TEE in the surgery-alone group (v
2
test P\.01). The relative risk of developing a TEE during
the whole treatment period for patients treated with che-
motherapy was 3.8 (95% conﬁdence interval 1.2–12.0; v
2
test P = .009). The relative risk for of developing a TEE
during the combined preoperative and postoperative period
was 3.6 (95% conﬁdence interval 1.1–11.4; chemotherapy
group, n = 16; surgery-alone group, n = 3; v
2 test
P = .014).
Preoperative Period
In the preoperative period, 14 patients were diagnosed
with a TEE. All of these TEEs occurred in the cohort of
chemotherapy patients (26.9%).
Patients receiving chemotherapy had a follow-up CT
scan for evaluation of response after the second preopera-
tive treatment cycle. This led to coincidental detection of
TEE in 6 cases. In 8 patients, the TEEs were symptomatic.
The median interval between CT scan for response evalu-
ation and surgery was 57 (range 7–91) days for patients
who received chemotherapy. The median time interval
between the last preoperative CT scan and surgery was 59
(range 1–92) days for the surgery-alone group (Mann-
Whitney U-test P = .915).
In all cases of TEE, anticoagulant therapy was initiated.
For 6 patients with preoperative TEE, chemotherapy was
stopped, and in 2 cases, only cisplatin therapy was stopped
(Table 5). The other 6 TEEs were discovered after the third
treatment cycle. None of the patients was excluded for
surgery. The median time to surgery from the last day of
chemotherapy was 34 (range 13–59) days for patients who
did not have a preoperative TEE and 38.5 (range 15–91)
days for patients with a preoperative TEE (Mann-Whitney
U-test P = .239).
Median postoperative hospital stay for patients with a
preoperative TEE was 14 (range 11–27) days and 17 (range
TABLE 3 continued
Characteristic Surgery alone (n = 35) Surgery and ECC (n = 52) P
a
Lymph nodes
Total resected, median (range) 19 (5–65) 20 (2–49) .396
c
Positive lymph nodes 23 (65.7%) 24 (46.2%) .073
Radicality (R0) 33 (94.3%) 50 (96.2%) .683
Length of hospital stay, days .137
c
Median 17 15
Range 10–105 10–46
BMI body mass index, DM diabetes mellitus, ASA American Society of Anesthesiologists, R0 resection margin free of microscopic tumor cells
a Chi-square test unless otherwise indicated
b Two-sample t-test
c Mann-Whitney U-test
TABLE 4 Number of TEEs during treatment in control and ECC
group
Treatment period TEE
grade
Surgery alone
(n = 35)
Surgery and ECC
(n = 52)
Preoperative Total 0 (0.0%) 14 (29.9%)
20 1
30 9
40 4
50 0
Postoperative Total 3 (8.6%) 3 (5.8%)
20 0
31 1
42 2
a
50 0
Postoperative
chemotherapy
Total NA 2 (3.8%)
2N A 0
3N A 0
4N A 2
b
5N A 0
NA not applicable
a One patient also had a preoperative TEE (grade 4)
b One patient also had a preoperative TEE (grade 3)
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U-test P = .325).
Postoperative Period
During the postoperative period, three TEEs occurred in
the chemotherapy group (5.8%). Another three events were
recorded in the surgery-alone group (8.6%, v
2 test
P = .613). None of the patients with postoperative TEE
was diagnosed with atrial ﬁbrillation. One of the patients
with postoperative TEE developed a thrombus in the left
ventricle during preoperative chemotherapy. In the other 5
cases, no preoperative TEEs occurred.
Median postoperative hospital stay for patients with a
postoperative TEE was 23 (range 14–78) days and 15
(range 10–105) days for patients without TEE (Mann-
Whitney U-test P = .126).
Postoperative Chemotherapy Period
After recovering from surgery, 21 of 52 patients contin-
uedchemotherapy.In 31cases,postoperative chemotherapy
was not administered for various reasons. Toxicity during
preoperative chemotherapy formed the main reason for not
receiving postoperative therapy (n = 16). Other reasons
were metastatic disease (n = 4), poor patient condition
(n = 6), death (n = 1), irradical resection (n = 1), and
withdrawn consent (n = 3).
Two patients developed a grade 4 TEE (cardiovascular
accident) during postoperative chemotherapy. One of these
patients already had deep venous thrombosis and pul-
monary embolism during preoperative therapy. Further
postoperative chemotherapy was discontinued in both
patients.
Risk Factors for Thromboembolic Complications
BesidespreoperativetreatmentwithECC,noneoftherisk
factors showed statistically signiﬁcant correlation with TEE
inunivariatelogisticregressionanalysis. Totestforpossible
confounders, all risk factors were analyzed for correlations
with the use of chemotherapy by univariate logistic regres-
sion (data not shown). Factors with a correlation P-value of
\.100were subjected tofurtheranalysis.AhistoryofCOPD
and length of stay were inversely correlated with the use of
preoperative chemotherapy (P = .051 and P = .042,
respectively). Transthoracic surgery and the presence of
positive lymph nodes in the resection specimen were posi-
tively correlated with the use of preoperative chemotherapy
(P = .041 and P = .075 respectively). To correct for pos-
sible confounding, these factors were included in
multivariate logistic regression analysis.
Table 6 provides an overview of the analyzed risk fac-
tors in univariate analysis as well as the possible
confounding risk factors in multivariate analysis. Preop-
erative chemotherapy was an independent predictor for
developing TEE during the combined preoperative and
postoperative period (P = .034). None of the possible
confounding risk factors contributed in a statistically sig-
niﬁcant way in multivariate analysis.
DISCUSSION
The current study shows that TEE is more frequent
among patients selected for perioperative treatment with
the ECC regimen compared to patients not receiving che-
motherapy. The majority of preoperative TEEs were grade
3 and 4, which are potentially lethal. In all cases, TEE
required medical intervention with anticoagulant therapy,
and in most cases the chemotherapy regimen was adjusted
or discontinued. However, preoperative TEE did not dis-
qualify patients for surgery; nor did it increase the risk of
postoperative TEE.
Somestudieshavespeciﬁcallyreportedontheprevalence
and signiﬁcance of venous thrombosis in gastroesophageal
cancer patients receiving palliative chemotherapy.
14,15 To
date,toourknowledge,nostudieshavereportedontheeffect
of TEE on perioperative outcomes in patients receiving
neoadjuvantECCtherapy.Thisstudyspeciﬁcallyfocuseson
patientswithEACcomparingpatientswhoreceiveaspeciﬁc
TABLE 5 Patients with preoperative TEEs and changes to their chemotherapy regimen
Change in preoperative regimen n Timing
Stop chemotherapy 1 During ﬁrst cycle
1 During second cycle
3 After second cycle
1 During third cycle
Stop cisplatin, switch to oxaliplatin 1 After ﬁrst cycle, completed second cycle with oxaliplatin, no third cycle
Stop cisplatin 1 After second cycle, completed third cycle without cisplatin
No change 6 TEE occurred after third cycle
a
Total 14
a In 4 patients, capecitabine dose was reduced because of polyneuropathy
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operative treatment in the same period. Hence, treatment
standards (e.g., surgical expertise and intensive care unit
protocols)werethesameforallpatients.However,selection
bias, by which patients are selected for chemotherapy, could
not be eliminated. Baseline characteristics show a less
advancedendoscopicallydeﬁnedtumorstage(uT),butalsoa
poorer patient condition in the surgery-alone group. None-
theless, TEE rates are higher in the chemotherapy group.
Postoperative pathologically deﬁned tumor stage (pT), par-
ticularly for advanced disease stage (pT3), is equal in both
groups.Hence,higherTstagedoesnotexplainthedifference
in TEE incidence observed in this study. Moreover, despite
certain baseline differences, multivariate analysis identiﬁed
chemotherapy as the only independent risk factor for pre-
operative and postoperative TEE.
The MAGIC trial did not describe excess thromboem-
bolic complications during treatment.
4 The authors did
recommend the use of prophylactic antithrombotic therapy.
The MAGIC regimen used continuous intravenous ﬂuoro-
uracil administration during 21 consecutive days and
recommended warfarin as a prophylaxis for intravenous
catheter–associated thrombosis. However, it remains
unclear what percentage of patients actually received pro-
phylaxis during the trial. Also, we may have detected more
subclinical TEEs as a result of the follow-up CT scan (for
response evaluation) in the chemotherapy group. Patients
from the surgery-alone group did not routinely undergo a
second CT scan before surgery. Nevertheless, the time
interval between the last preoperative CT scan and surgery
was equal in both groups. Furthermore, 8 out of 14 pre-
operative TEEs were symptomatic. The observed TEE rate
in our analysis of the preoperative chemotherapy group
suggests that without prophylaxis, a high TEE rate can be
expected.
All patients with preoperative TEE received anticoagu-
lant therapy until surgery. The subsequent effect on
postoperative TEE cannot be measured in this study.
Careful monitoring by the medical oncologist and early
intervention has proved to prevent worsening of thrombo-
embolic disease and most probably prevented postoperative
events. Only 1 patient with a preoperative TEE also
developed a postoperative TEE. The other 5 patients with
postoperative TEE did not use anticoagulant therapy in the
preoperative period.
During the last year of the inclusion period, several
candidates for perioperative therapy were given an alterna-
tive regimen in which cisplatin (ECC therapy) was replaced
by oxaliplatin (EOC therapy). Oxaliplatin is as effective as
cisplatininthetreatmentofpatientswithuntreatedadvanced
TABLE 6 Univariate and multivariate analysis of the association between risk factors and development of TEE during the combined preop-
erative and postoperative period
Characteristic Unadjusted OR (95% CI), univariate P Adjusted OR (95% CI), multivariate
a P
Gender (male) 0.804 (0.226–2.853) .735
Age (continuous) 0.988 (0.934–1.046) .684
Age ([60 years) 0.840 (0.279–2.531) .757
BMI ([27) 0.900 (0.325–2.492) .839
TEE in history 1.620 (0.552–4.755) .380
DM 0.549 (0.122–2.698) .460
Hypertension 0.659 (0.224–1.944) .450
COPD 0.454 (0.094–2.200) .327 0.687 (0.130–3.634) .659
Smoking 1.223 (0.474–3.151) .677
Positive LN 0.931 (0.336–2.580) .891 1.347 (0.445–4.070) .598
Tumor differentiation grade 0.958 (0.682–1.345) .803
LOS 0.999 (0.964–1.036) .967 1.014 (0.975–1.054) .501
ASA score 0.534 (0.235–1.211) .133
Operation time 1.002 (0.997–1.008) .458
Transthoracic surgery 1.733 (0.559–5.378) .341 1.129 (0.334–3.817) .845
Open surgery 0.353 (0.074–1.687) .192
Anticoagulant therapy 0.484 (0.056–4.199) .510
Chemotherapy 4.741 (1.264–17.780) .021 4.937 (1.131–21.545) .034
CI conﬁdence interval, BMI body mass index, DM diabetes mellitus, LN lymph node, LOS length of hospital stay, ASA American Society of
Anesthesiologists
a Included for multivariate regression analysis were possible confounders (i.e., risk factors that showed univariate association (P\.100) with
chemotherapy)
690 R. J. J. Verhage et al.gastroesophageal cancer, but it is associated with a lower
incidence of thromboembolism
8,16,17
In 1 patient with preoperative TEE during the ﬁrst
treatment cycle, ECC was changed to EOC therapy. This
patient did not receive a third treatment cycle. In another
patient with TEE discovered after the second treatment
cycle, cisplatin was not administered during the third cycle.
In the other 6 cases, ECC therapy was changed to EOC
therapy for reasons of ototoxicity (n = 2) and nephrotox-
icity (n = 4). Because patients received ECC during the
ﬁrst treatment cycle, and on the basis of the intention-to-
treat principle, these patients were included in our analysis.
This has possibly caused an underestimation of the TEE
rate in the ECC cohort. Though speculative, it could be
argued that without the alternative EOC regimen, preop-
erative and postoperative TEE rates would have turned out
higher. It must, however, be noted that there is no evidence
that oxaliplatin is preferred over cisplatin in the curative
perioperative setting with respect to survival and toxicity.
Because transthoracic surgery takes more time and
includes more extensive dissection than transhiatal surgery,
it could be argued that operative approach might inﬂuence
postoperative TEE rates. However, operative approach as a
possible confounder was not correlated with TEE in mul-
tivariate analysis. With respect to postoperative recovery,
no negative effects of chemotherapy were noticed. The
median hospital stay was similar in both study groups. In
addition, experiencing TEE during the preoperative period
was not associated with increased postoperative hospital
stay. Though not statistically signiﬁcant, median hospital
stay was increased with 7 days for patients who experi-
enced a postoperative TEE.
Because venous thrombotic events can extend beyond
the inpatient recovery period, the postoperative period
included inpatient hospital stay as well as the postdis-
charge period up to 30 days after initial surgery.
18
Despite this extended period, there was no observation of
symptomatic TEE in the outpatient clinic. Moreover,
there was no increased incidence of postoperative TEE
within the group of patients who experienced a preop-
erative TEE.
Perioperative treatment with the ECC regimen
improves survival in patients with EAC, but this beneﬁt is
accompanied by toxicity that could seriously harm
patients and their surgical outcomes. The current study
showed that TEE was frequent and was independently
associated with chemotherapy. Although they were treated
adequately, preoperative TEEs did not greatly inﬂuence
time to surgery, hospital stay, or the occurrence of post-
operative TEE. Nonetheless, in each individual case, it
should be evaluated whether the beneﬁts of the ECC
regimen outweigh the increased risk of TEE. All patients
who receive preoperative chemotherapy according to the
ECC regimen should undergo a follow-up CT scan after
the second treatment cycle. Imaging should not only focus
on treatment evaluation, but also on signs of thrombo-
embolic disease.
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